Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial

Abstract Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yung-Tsan Wu, Tsung-Yen Ho, Yu-Ching Chou, Ming-Jen Ke, Tsung-Ying Li, Guo-Shu Huang, Liang-Cheng Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a6acc067144b4b7bb0bdc40536431ba2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6acc067144b4b7bb0bdc40536431ba2
record_format	dspace
spelling	oai:doaj.org-article:a6acc067144b4b7bb0bdc40536431ba22021-12-02T15:05:43ZSix-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial10.1038/s41598-017-00224-62045-2322https://doaj.org/article/a6acc067144b4b7bb0bdc40536431ba22017-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00224-6https://doaj.org/toc/2045-2322Abstract Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-blind, controlled trial to assess the 6-month effect of PRP in patients with CTS. Sixty patients with unilateral mild-to-moderate CTS were randomized into two groups of 30, namely the PRP and control groups. In the PRP group, patients were injected with one dose of 3 mL of PRP using ultrasound guidance and the control group received a night splint through the study period. The primary outcome measure was the visual analog scale (VAS) and secondary outcome measures included the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score, the cross-sectional area (CSA) of the median nerve (MN), electrophysiological findings of the MN, and finger pinch strength. The evaluation was performed before treatment and at 1, 3, and 6 months post-injection. The PRP group exhibited a significant reduction in the VAS score, BCTQ score, and CSA of MN compared to the those of control group 6 months post-treatment (p < 0.05). Our study demonstrates that PRP is a safe modality that effectively relieves pain and improves disability in the patients with CTS.Yung-Tsan WuTsung-Yen HoYu-Ching ChouMing-Jen KeTsung-Ying LiGuo-Shu HuangLiang-Cheng ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yung-Tsan Wu Tsung-Yen Ho Yu-Ching Chou Ming-Jen Ke Tsung-Ying Li Guo-Shu Huang Liang-Cheng Chen Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
description	Abstract Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-blind, controlled trial to assess the 6-month effect of PRP in patients with CTS. Sixty patients with unilateral mild-to-moderate CTS were randomized into two groups of 30, namely the PRP and control groups. In the PRP group, patients were injected with one dose of 3 mL of PRP using ultrasound guidance and the control group received a night splint through the study period. The primary outcome measure was the visual analog scale (VAS) and secondary outcome measures included the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score, the cross-sectional area (CSA) of the median nerve (MN), electrophysiological findings of the MN, and finger pinch strength. The evaluation was performed before treatment and at 1, 3, and 6 months post-injection. The PRP group exhibited a significant reduction in the VAS score, BCTQ score, and CSA of MN compared to the those of control group 6 months post-treatment (p < 0.05). Our study demonstrates that PRP is a safe modality that effectively relieves pain and improves disability in the patients with CTS.
format	article
author	Yung-Tsan Wu Tsung-Yen Ho Yu-Ching Chou Ming-Jen Ke Tsung-Ying Li Guo-Shu Huang Liang-Cheng Chen
author_facet	Yung-Tsan Wu Tsung-Yen Ho Yu-Ching Chou Ming-Jen Ke Tsung-Ying Li Guo-Shu Huang Liang-Cheng Chen
author_sort	Yung-Tsan Wu
title	Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
title_short	Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
title_full	Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
title_fullStr	Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
title_full_unstemmed	Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
title_sort	six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: a prospective randomized, single-blind controlled trial
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a6acc067144b4b7bb0bdc40536431ba2
work_keys_str_mv	AT yungtsanwu sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT tsungyenho sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT yuchingchou sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT mingjenke sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT tsungyingli sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT guoshuhuang sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT liangchengchen sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial
_version_	1718388722852954112

Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial

Ejemplares similares